These Healthcare Stocks Are Overvalued
Healthcare has become one of the main havens this year for capital fleeing the technology sector. Its defensive reputation, record results and several breakthrough clinical data readouts have driven some very familiar names to valuations that, until recently, were reserved for fast-growing software companies. We looked at 4 stocks whose prices are running ahead of their fundamentals according to key metrics, and examined where the premium is justifiable and where the market is already paying for a future that has yet to arrive.

Key points
A pharmaceutical giant worth more than $1 trillion is valued at 2.6 times more than its biggest rival, even though its realized prices are falling this year.
A trailing P/E of around 50 for one dividend stock is largely an accounting illusion; the real risk is on the balance sheet.
The best-performing stock in this year's S&P 500 trades at roughly 36 times sales, and the company has just announced that costs will stop falling.
The leader in surgical robotics is growing by 22%, but procedure growth in the US has slowed for the fifth consecutive quarter.
Why is none of this a signal to sell immediately, but instead a sign of a significantly worse risk-reward profile?
2026 has brought a marked rotation in the US market. While technology stocks came under pressure from massive investments in artificial intelligence, investors looked for sectors with more predictable earnings. Healthcare benefited the most. In October alone, one major pharmaceutical company was among the market's best-performing stocks, gaining more than 23%, while the Nasdaq 100 lost nearly 7% over the same month.
The problem is that a defensive sector stops being cheap when too much money flows into it. For several well-known names, valuation multiples have reached levels that assume near-perfect execution for years to come. Those expectations are not necessarily wrong, but they leave very little room for disappointment. A weak quarter, regulatory intervention in drug prices or a delayed approval could send high-premium stocks down much faster than the market.
This analysis separates two things that are often conflated in valuations for each company. The first is the quality of the business, which is above average for all 4 names. The second is the price the market is demanding for that quality today. You'll also find warnings about cases where common metrics such as trailing P/E are distorted by a one-off accounting item. If you need a refresher on how to read P/E, forward P/E or PEG, you'll find explanations in the Bulios Academy. Now let's take a look at each company.